Cargando…
IFN-I-tolerant oncolytic Semliki Forest virus in combination with anti-PD1 enhances T cell response against mouse glioma
Oncolytic virotherapy holds promise of effective immunotherapy against otherwise nonresponsive cancers such as glioblastoma. Our previous findings have shown that although oncolytic Semliki Forest virus (SFV) is effective against various mouse glioblastoma models, its therapeutic potency is hampered...
Autores principales: | Martikainen, Miika, Ramachandran, Mohanraj, Lugano, Roberta, Ma, Jing, Martikainen, Minttu-Maria, Dimberg, Anna, Yu, Di, Merits, Andres, Essand, Magnus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042242/ https://www.ncbi.nlm.nih.gov/pubmed/33869741 http://dx.doi.org/10.1016/j.omto.2021.03.008 |
Ejemplares similares
-
Insertion of the Type-I IFN Decoy Receptor B18R in a miRNA-Tagged Semliki Forest Virus Improves Oncolytic Capacity but Results in Neurotoxicity
por: Sarén, Tina, et al.
Publicado: (2017) -
Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer
por: Ma, Jing, et al.
Publicado: (2020) -
Concurrent expression of HP-NAP enhances antitumor efficacy of oncolytic vaccinia virus but not for Semliki Forest virus
por: Ma, Jing, et al.
Publicado: (2021) -
Virus-Based Immunotherapy of Glioblastoma
por: Martikainen, Miika, et al.
Publicado: (2019) -
Tumor angiogenesis: causes, consequences, challenges and opportunities
por: Lugano, Roberta, et al.
Publicado: (2019)